



Resultados

1T25



Legal notice



This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements are based on the beliefs and assumptions of our management and information to which the Company currently has access. Forward-looking statements include information about our current intentions, beliefs or expectations, as well as those of the members of the Company's Board of Directors and Officers.

Disclaimers regarding forward-looking statements and information also include information about potential or expected operating results, as well as statements that are preceded, followed or that include the words "believes", "may", "will", "continues", "expects", "predicts", "intends", "plans", "estimates" or similar expressions.

Forward-looking statements and information are not guarantees of performance. They involve risks, uncertainties and assumptions because they refer to future events, depending, therefore, on events that may or may not occur. Future results and value creation for shareholders may differ significantly from those expressed or suggested by forward-looking statements. Many of the factors that will determine these results and values are beyond our ability to control or predict.

Highlights 1Q25



Consolidated Net Revenue

6.3% growth, reaching R\$ 189.6 million.

Growth in gross margin.



8 launches in the last 12 months, through internal development, partnerships and new business.

Highlights 1Q25

1Q25 Launches

Production Animals



LeanVac

A melhor opção é a
liberdade de escolha



Controle dos níveis de
androgenona e escatol



Eficácia e segurança



Produtividade sem risco



Viva novos caminhos
de forma **eficaz**
e **segura** com
LeanVac, a nova
escolha para
imunocastração.

Boostin[®] agora é Ourofino



Financial Highlights



Growth in Companion Animals, representing 7.9% when compared to 1Q24.

Growth in International Operations, representing 45.1% When compared to 1T24.



Growth in gross margin +0.5 bps.




Leverage at 0.9x EBITDA, with 84.6% of the debt in the long term and an average cost of 8.42% year to date.


Consolidated Results

Net revenue of R\$ 189.6 million. 6.3 % growth in the quarter. Gross margin reaches 48.5%

Net revenue - R\$ million



Gross profit - R\$ million




Production Animal Results


Foot-and-mouth disease: Ex. FMD, net revenue grows by 6.2%, given that we had R\$ 7.4 million in net revenue from the foot-and-mouth disease vaccine in 1Q24.

The impact on the gross margin is the result of a less favorable mix in cattle and equine products, and a higher share from the poultry and swine segment.


Net revenue - R\$ million



Net revenue (ex. FMD) - R\$ million



Gross profit - R\$ million




Companion Animals Results


Net revenue of R\$36.6 million, representing a 7.9% increase compared to 1Q24.

Gross margin increases by 5.1 p.p., reaching 67.5% in 1Q25.

Net revenue - R\$ million



Gross profit - R\$ million




International Operations Results


Net revenue of R\$27.5 million, representing a 45.1% increase compared to 1Q24. This growth reflects the high sales volume during the period, mainly in Central American countries.

Gross profit of R\$17.7 million, with a margin of 64.2%, representing a growth of 11.3 p.p.

Net revenue - R\$ million



Gross profit - R\$ million




Adjusted SG&A

Adjusted SG&A totaled R\$71.6 million, representing 37.8% of net revenue – a 10.1% increase compared to 1Q24.

Impacted by strategic investments in commercial and marketing structures, in line with the growth plan of the business units.

SG&A - R\$ million




Research & Development Investments

R&D investments reached 9.9% of net revenue in 1Q25, totaling R\$18.7 million.

The amount invested is aligned with the strategy of expanding the product portfolio, aiming to ensure future revenue and generate value for the business.

Research and Development Expenditure- R\$ million




Adjusted EBITDA

Adjusted EBITDA showed a decrease of -22.8% compared to 1Q24.

The decrease in EBITDA is primarily a result of higher expenses in R&D and investments in the commercial structure.

Adjusted EBITDA - R\$ million




Generation of CASH

Operating cash generation reached R\$57.7 million in 1Q25, totaling cash availability of R\$148.5 million.

*Capital reduction carried out in January 2025.

Cash Position - R\$ Million




*We remind that on January 31, 2025, as previously communicated and approved at the Extraordinary General Meeting held in October 2024, we made a capital reduction payment of R\$120 million to shareholders. This move is aligned with our strategy of creating value for all shareholders, without compromising the company's growth or investment capacity, in line with the leverage over the last four years.


With our robust cash generation, we have already managed to reintegrate nearly 50% of the amount distributed to shareholders within the first few months of the year. We reaffirm, therefore, the strong cash generation and conversion capacity of the operation, as well as the efficiency of the financial management, which ensures a solid structure aligned with the strategic needs of Ourofino.

Share Capital Structure



Leverage of 0.9x EBITDA and year-to-date average debt cost of 8.42%, with 84.6% of the debt maturing in over 5 years..



Composition



Share Capital Structure



Q&A

Reimagining Animal Health

We produce solutions and services to feed the world and increase the longevity of companion animals.





Ourofino S.A.
(B3:OFSA3)

Investor Relations

Department



ri@ourofino.com



(16) 3518-4098



ri.ourofino.com

Marcelo Silva

Lucas Britto